“Live” Cyberplasm Microbot Designed for Disease Detection
|
By LabMedica International staff writers Posted on 11 Apr 2012 |
A “living” prototype microbot is under development that could someday identify diseases in humans.
Called Cyberplasm, it will combine advanced microelectronics with latest developments in biomimicry (technology inspired by nature). The goal is for Cyberplasm to have an electronic nervous system, “eye” and “nose” sensors derived from mammalian cells, as well as artificial muscles that utilize glucose as an energy source to propel it. The key purpose is to engineer and incorporate robot components that respond to light and chemicals in the same way as biologic systems. This is a totally new way of utilizing robotics technology.
Cyberplasm is being developed over the next few years as part of an international collaboration funded by the UK Engineering and Physical Sciences Research Council (EPSRC) and the US National Science Foundation (NSF; Arlington, VA, USA). The UK-based work is taking place at Newcastle University (UK). The project originated from a sandbox session on synthetic biology jointly funded by the two organizations.
Cyberplasm will be devised to mimic key functions of the sea lamprey, a creature found mostly in the Atlantic Ocean. It is believed this application will enable the microbot to be very sensitive and responsive to any environment into which it is placed. Future uses could include the ability to swim inconspicuously through the human body to detect a wide host of diseases.
The sea lamprey [Petromyzon marinus] has a very primitive nervous system, which is easier to mimic than more complicated nervous systems. This, combined with the fact that it swims, made the sea lamprey the best candidate for the scientists on which to base Cyberplasm.
Once it is developed, the Cyberplasm prototype will be less than 1-cm long. Future versions could possibly be less than 1-mm long or even constructed on a nanoscale. “Nothing matches a living creature’s natural ability to see and smell its environment and therefore to collect data on what's going on around it,” said bioengineer Dr. Daniel Frankel of Newcastle University, who is leading the UK-based work.
Cyberplasm’s sensors are being developed to respond to external stimuli by transforming them into electronic impulses that are sent to an electronic “brain” equipped with sophisticated microchips. This brain will then send electronic messages to artificial muscles instructing them how to contract and relax, enabling the robot to navigate its way safely using an undulating motion. Similarly, data on the chemical composition of the robot’s surroundings can be collected and stored via these systems for later recovery by the robot’s operators.
Cyberplasm could also represent the beginning of important advances in, for example, sophisticated prosthetics where living muscle tissue might be engineered to contract and relax in response to stimulation from light waves or electronic signals. “We’re currently developing and testing Cyberplasm’s individual components,” stated Daniel Frankel. “We hope to get to the assembly stage within a couple of years. We believe Cyberplasm could start being used in real-world situations within five years.”
The UK component of the Cyberplasm project is a three-year initiative that is receiving EPSRC funding of just over GBP 298,000. EPSRC is the main UK government agency for funding research and training in engineering and the physical sciences, investing more than GBP 800 million a year in a wide range of topics--from mathematics to materials science, and from information technology (IT) to structural engineering.
NSF is an independent US agency created by the US Congress in 1950. With an annual budget of approximately USD 6.9 billion (FY 2010), it is the funding source for about 20% of all federally-supported basic research conducted by US colleges and universities. In many fields, such as mathematics, computer science and the social sciences, NSF is the major source of federal backing.
Related Links:
UK Engineering and Physical Sciences Research Council
US National Science Foundation
Newcastle University
Called Cyberplasm, it will combine advanced microelectronics with latest developments in biomimicry (technology inspired by nature). The goal is for Cyberplasm to have an electronic nervous system, “eye” and “nose” sensors derived from mammalian cells, as well as artificial muscles that utilize glucose as an energy source to propel it. The key purpose is to engineer and incorporate robot components that respond to light and chemicals in the same way as biologic systems. This is a totally new way of utilizing robotics technology.
Cyberplasm is being developed over the next few years as part of an international collaboration funded by the UK Engineering and Physical Sciences Research Council (EPSRC) and the US National Science Foundation (NSF; Arlington, VA, USA). The UK-based work is taking place at Newcastle University (UK). The project originated from a sandbox session on synthetic biology jointly funded by the two organizations.
Cyberplasm will be devised to mimic key functions of the sea lamprey, a creature found mostly in the Atlantic Ocean. It is believed this application will enable the microbot to be very sensitive and responsive to any environment into which it is placed. Future uses could include the ability to swim inconspicuously through the human body to detect a wide host of diseases.
The sea lamprey [Petromyzon marinus] has a very primitive nervous system, which is easier to mimic than more complicated nervous systems. This, combined with the fact that it swims, made the sea lamprey the best candidate for the scientists on which to base Cyberplasm.
Once it is developed, the Cyberplasm prototype will be less than 1-cm long. Future versions could possibly be less than 1-mm long or even constructed on a nanoscale. “Nothing matches a living creature’s natural ability to see and smell its environment and therefore to collect data on what's going on around it,” said bioengineer Dr. Daniel Frankel of Newcastle University, who is leading the UK-based work.
Cyberplasm’s sensors are being developed to respond to external stimuli by transforming them into electronic impulses that are sent to an electronic “brain” equipped with sophisticated microchips. This brain will then send electronic messages to artificial muscles instructing them how to contract and relax, enabling the robot to navigate its way safely using an undulating motion. Similarly, data on the chemical composition of the robot’s surroundings can be collected and stored via these systems for later recovery by the robot’s operators.
Cyberplasm could also represent the beginning of important advances in, for example, sophisticated prosthetics where living muscle tissue might be engineered to contract and relax in response to stimulation from light waves or electronic signals. “We’re currently developing and testing Cyberplasm’s individual components,” stated Daniel Frankel. “We hope to get to the assembly stage within a couple of years. We believe Cyberplasm could start being used in real-world situations within five years.”
The UK component of the Cyberplasm project is a three-year initiative that is receiving EPSRC funding of just over GBP 298,000. EPSRC is the main UK government agency for funding research and training in engineering and the physical sciences, investing more than GBP 800 million a year in a wide range of topics--from mathematics to materials science, and from information technology (IT) to structural engineering.
NSF is an independent US agency created by the US Congress in 1950. With an annual budget of approximately USD 6.9 billion (FY 2010), it is the funding source for about 20% of all federally-supported basic research conducted by US colleges and universities. In many fields, such as mathematics, computer science and the social sciences, NSF is the major source of federal backing.
Related Links:
UK Engineering and Physical Sciences Research Council
US National Science Foundation
Newcastle University
Latest BioResearch News
- Genome Analysis Predicts Likelihood of Neurodisability in Oxygen-Deprived Newborns
- Gene Panel Predicts Disease Progession for Patients with B-cell Lymphoma
- New Method Simplifies Preparation of Tumor Genomic DNA Libraries
- New Tool Developed for Diagnosis of Chronic HBV Infection
- Panel of Genetic Loci Accurately Predicts Risk of Developing Gout
- Disrupted TGFB Signaling Linked to Increased Cancer-Related Bacteria
- Gene Fusion Protein Proposed as Prostate Cancer Biomarker
- NIV Test to Diagnose and Monitor Vascular Complications in Diabetes
- Semen Exosome MicroRNA Proves Biomarker for Prostate Cancer
- Genetic Loci Link Plasma Lipid Levels to CVD Risk
- Newly Identified Gene Network Aids in Early Diagnosis of Autism Spectrum Disorder
- Link Confirmed between Living in Poverty and Developing Diseases
- Genomic Study Identifies Kidney Disease Loci in Type I Diabetes Patients
- Liquid Biopsy More Effective for Analyzing Tumor Drug Resistance Mutations
- New Liquid Biopsy Assay Reveals Host-Pathogen Interactions
- Method Developed for Enriching Trophoblast Population in Samples
Channels
Clinical Chemistry
view channel
New PSA-Based Prognostic Model Improves Prostate Cancer Risk Assessment
Prostate cancer is the second-leading cause of cancer death among American men, and about one in eight will be diagnosed in their lifetime. Screening relies on blood levels of prostate-specific antigen... Read more
Extracellular Vesicles Linked to Heart Failure Risk in CKD Patients
Chronic kidney disease (CKD) affects more than 1 in 7 Americans and is strongly associated with cardiovascular complications, which account for more than half of deaths among people with CKD.... Read moreMolecular Diagnostics
view channel
Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test
Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more
Blood Test Detects Early-Stage Cancers by Measuring Epigenetic Instability
Early-stage cancers are notoriously difficult to detect because molecular changes are subtle and often missed by existing screening tools. Many liquid biopsies rely on measuring absolute DNA methylation... Read more
“Lab-On-A-Disc” Device Paves Way for More Automated Liquid Biopsies
Extracellular vesicles (EVs) are tiny particles released by cells into the bloodstream that carry molecular information about a cell’s condition, including whether it is cancerous. However, EVs are highly... Read more
Blood Test Identifies Inflammatory Breast Cancer Patients at Increased Risk of Brain Metastasis
Brain metastasis is a frequent and devastating complication in patients with inflammatory breast cancer, an aggressive subtype with limited treatment options. Despite its high incidence, the biological... Read moreHematology
view channel
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read more
Fast and Easy Test Could Revolutionize Blood Transfusions
Blood transfusions are a cornerstone of modern medicine, yet red blood cells can deteriorate quietly while sitting in cold storage for weeks. Although blood units have a fixed expiration date, cells from... Read more
Automated Hemostasis System Helps Labs of All Sizes Optimize Workflow
High-volume hemostasis sections must sustain rapid turnaround while managing reruns and reflex testing. Manual tube handling and preanalytical checks can strain staff time and increase opportunities for error.... Read more
High-Sensitivity Blood Test Improves Assessment of Clotting Risk in Heart Disease Patients
Blood clotting is essential for preventing bleeding, but even small imbalances can lead to serious conditions such as thrombosis or dangerous hemorrhage. In cardiovascular disease, clinicians often struggle... Read moreImmunology
view channelBlood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug
Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more
Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment
Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more
Ultrasensitive Liquid Biopsy Demonstrates Efficacy in Predicting Immunotherapy Response
Immunotherapy has transformed cancer treatment, but only a small proportion of patients experience lasting benefit, with response rates often remaining between 10% and 20%. Clinicians currently lack reliable... Read moreMicrobiology
view channel
Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease
Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read moreAI-Powered Platform Enables Rapid Detection of Drug-Resistant C. Auris Pathogens
Infections caused by the pathogenic yeast Candida auris pose a significant threat to hospitalized patients, particularly those with weakened immune systems or those who have invasive medical devices.... Read morePathology
view channel
Engineered Yeast Cells Enable Rapid Testing of Cancer Immunotherapy
Developing new cancer immunotherapies is a slow, costly, and high-risk process, particularly for CAR T cell treatments that must precisely recognize cancer-specific antigens. Small differences in tumor... Read more
First-Of-Its-Kind Test Identifies Autism Risk at Birth
Autism spectrum disorder is treatable, and extensive research shows that early intervention can significantly improve cognitive, social, and behavioral outcomes. Yet in the United States, the average age... Read moreTechnology
view channel
Robotic Technology Unveiled for Automated Diagnostic Blood Draws
Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more
ADLM Launches First-of-Its-Kind Data Science Program for Laboratory Medicine Professionals
Clinical laboratories generate billions of test results each year, creating a treasure trove of data with the potential to support more personalized testing, improve operational efficiency, and enhance patient care.... Read moreAptamer Biosensor Technology to Transform Virus Detection
Rapid and reliable virus detection is essential for controlling outbreaks, from seasonal influenza to global pandemics such as COVID-19. Conventional diagnostic methods, including cell culture, antigen... Read more
AI Models Could Predict Pre-Eclampsia and Anemia Earlier Using Routine Blood Tests
Pre-eclampsia and anemia are major contributors to maternal and child mortality worldwide, together accounting for more than half a million deaths each year and leaving millions with long-term health complications.... Read moreIndustry
view channelNew Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing
Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
AI-Powered Cervical Cancer Test Set for Major Rollout in Latin America
Noul Co., a Korean company specializing in AI-based blood and cancer diagnostics, announced it will supply its intelligence (AI)-based miLab CER cervical cancer diagnostic solution to Mexico under a multi‑year... Read more
Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform
Diasorin (Saluggia, Italy) has entered into an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific (Waltham, MA, USA), for the LIAISON NES molecular point-of-care... Read more







